Prostate Cancer Nuclear Medicine Diagnostics Market Share, Assumptions & Limitations By Forecast To 2028

According to Premium Market Insights new research study on "Prostate Cancer Nuclear Medicine Diagnostics Market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.

Get a Sample Copy of This Report@ https://www.premiummarketinsights.com/sample/TIP00073520/?utm_source=OpenPR&utm_medium=10655

Some Of the Major Players Influencing are Blue Earth Diagnostics Limited, ImaginAB, Curium, Jubilant Radiopharma, NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH, Telix Pharmaceuticals Ltd., Novartis AG, Theragonostics, Lantheus Medical Imaging Inc.

Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer.
In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.

Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging.

Inquiry Before Buying At: https://www.premiummarketinsights.com/inquiry/TIP00073520/?utm_source=OpenPR&utm_medium=10655

Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through
National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share.

A few of the key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS).

Order a copy of this research study at- https://www.premiummarketinsights.com/buy/TIP00073520/?utm_source=OpenPR&utm_medium=10655

In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.

Table Of Contents
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By Type
1.3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By PET Product
1.3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By End User
1.3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market - By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Prostate Cancer Nuclear Medicine Diagnostics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East And Africa PEST Analysis
4.2.5 South And Central America PEST Analysis
4.3 Experts Opinion
5. Prostate Cancer Nuclear Medicine Diagnostics Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Prostate Cancer
5.1.2 Surging Demand for Early and Precise Diagnosis of Prostate Cancer
5.2 Market Restraints
5.2.1 High Cost Related to the Prostate Cancer Diagnostics and Treatment
5.3 Market Opportunities
5.3.1 Growing Use of Radiopharmaceuticals in Prostate Cancer
5.4 Future Trends
5.4.1 Increasing Research Activities for Development of Innovative Imaging Agents
5.5 Impact Analysis
Continued…...!

Contact Us:
If you have any queries pertaining to the report or would like further information, feel free to reach out to us at-
Contact Person: Sameer Joshi
E-mail: sales@premiummarketinsights.com
Phone: +1-646-491-9876

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

This release was published on openPR.